FPMAJ Subcommittee Calls for Caution on “Simply Adding 2% to NHI Prices in Conjunction with Sales Tax Hike” in FY2017 Revision

June 16, 2015
A study report announced on June 12 by the subcommittee on listed drugs of the Federation of Pharmaceutical Manufacturers’ Associations of Japan’s (FPMAJ) NHI Drug Pricing Committee states that NHI price reductions based on actual market prices “should not be...read more